TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04938752
Drug: DA-2811-R
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (one tablet once a day)
Study: NCT05864391
Drug: AZD7503
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant is expected to be in the study for approximately 24 weeks, including a screening period of up to 28 days, a 12-week study intervention period, and a follow-up visit at week 18 (10 weeks following the final dose). Participants will be randomly assigned in a 3:1 ratio to receive AZD7503 or placebo. Study intervention will be administered via subcutaneous injection.
Study: NCT04502394
Drug: KRT-232
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth
Study: NCT05330429
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT05330429
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT05354817
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFIRINOX: - Oxaliplatin; Leucovorin; Irinotecan and 5-FU
Study: NCT05517616
Drug: [14C ]APG-2575
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, single dose of 400 mg / 200 μCi \[14C\] APG-2575
Study: NCT05512182
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab : 200mg/Q3W/IV infusion/Day 1of each 3-week cycle Neratinib : Week 1: 120 mg, Week 2: 160 mg, Week 3 and onwards: 240 mg/QD/Oral/Once daily Paclitaxel : 175mg/m2 /Q3W/IV infusion/Day 1of each 3-week cycle
Study: NCT05507515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching ONO-2020 tablets
Study: NCT05985590
Drug: Drospirenone/Ethinyl Estradiol
Normalized name: DROSPIRENONE/ETHINYL ESTRADIOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04530149
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: receive ketamine 0.15 mg/kg IV in 100 mL normal saline over 30 minutes for pain
Study: NCT06246162
Drug: Lipo-MIT combination regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial diagnosis induction treatment regimen Lipo-MIT +VD (VMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Bortezomib: 1.3mg/m2 d1, 4, 8, 11, subcutaneous injection; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of VMD regimen induction therapy are performed.~Reinduction therapy regimen after relapse Lipo-MIT + PD (PMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Pomalidomide: 4 mg/d d1-d21, orally; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of PMD regimen induction therapy are performed.
Study: NCT05193292
Drug: XELOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin, 130 mg/m2, iv, d1; Capecitabine, 1000 mg/m2, po, bid, d1-d14; q3w
Study: NCT05193292
Drug: mFOLFOX6 regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin, 85 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)\*2d, civ, 46h; q2w
Study: NCT05193292
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan, 180 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)\*2d, civ, 46h; q2w
Study: NCT05193292
Drug: mXELIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan, 200 mg/m2, iv, d1; capecitabine, 800 mg/m2, po, bid, d1-d14; q3w
Study: NCT05193292
Drug: mIRIS regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan, 180 mg/m2, iv, d1; Tiggio Capsules (S-1), 40-60 mg/m2, po, bid, d1-d9; q2w
Study: NCT05459519
Drug: Dengzhanxixin Capsule plus Placebo Capsule
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengzhanxixin Capsule, 0.54g (3 capsules) each time, twice daily; placebo, 1 capsule, twice daily
Study: NCT05459519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 4 capsules each time, twice daily
Study: NCT05459519
Drug: Dengzhanxixin Capsule plus Placebo Capsule
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengzhanxixin Capsule, 0.72g (4 capsules) each time, once daily; placebo, 4 capsules, once daily
Study: NCT04771780
Drug: KHK7791
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT05280223
Drug: Hyalase
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
Study: NCT06427863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive three consecutive enemas of placebo of equal volume through the TET tube, followed by WMT treatment once daily for a duration of 3 days
Study: NCT04709406
Drug: deep neuromuscular blockade in bariatric surgery
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: obese patients who underwent bariatric surgery
Study: NCT06181695
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of intranasal sufentanil
Study: NCT05412160
Drug: Arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During the first assessment the patients will be randomized to receive BioArginine C™ twice daily on top of chronic inhaled therapy or to continue their chronic Inhaled therapy plus placebo for 6 weeks. The main purpose is to compare changes in CRQ from baseline and after 6 weeks in the interventional arm compared with the control group in order to evaluate whether in symptomatic patients with COPD, daily bioarginine on top of chronic inhaled therapy can improve respiratory symptoms and dyspnea. The secondary objective of the study is to determine whether there is any correlation between improvement in respiratory symptoms and distance walked at the 6MWT and lung function parameters.
Study: NCT06704555
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 IV day 3
Study: NCT06704555
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 IV day 3
Study: NCT06706388
Drug: nL-ATN1-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized antisense oligonucleotide
Study: NCT05412160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the first assessment the patients will be randomized to receive BioArginine C™ twice daily on top of chronic inhaled therapy or to continue their chronic Inhaled therapy plus placebo for 6 weeks. The main purpose is to compare changes in CRQ from baseline and after 6 weeks in the interventional arm compared with the control group in order to evaluate whether in symptomatic patients with COPD, daily bioarginine on top of chronic inhaled therapy can improve respiratory symptoms and dyspnea. The secondary objective of the study is to determine whether there is any correlation between improvement in respiratory symptoms and distance walked at the 6MWT and lung function parameters.
Study: NCT06079931
Drug: Babaodan Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient received 66-66Gy/30-33F radiation therapy. During radiation therapy, concurrent chemotherapy includes receiving 45mg/m2 paclitaxel and carboplatin (AUC 2) once a week; From the start of radiation therapy to 2 months after the completion of CCRT, the patient takes 2 capsules of Babaodan orally every day, tid (1.8 g/day), and systemic corticosteroids can be used for acute radiation pneumonia patients with G ≥ 2.
Study: NCT05648006
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2, orally administered twice a day, D1 to D14, repeated every 3 weeks
Study: NCT06228365
Drug: Neuroleptanalgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual neuroleptanalgesic treatment
Study: NCT05621499
Drug: HAIC
Normalized name: Hepatic Arterial Infusion Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m2, LV 400 mg/ m2, 5-FU 400 mg/m2 bolus and then 2400 mg/m2 as 46h continuous infusion，Q3W，a total of 2 cycles
Study: NCT05373186
Drug: Euglycemic clamp with BC Combo THDB0207
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure
Study: NCT05373186
Drug: Euglycemic clamp with Humalog® Mix25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a single dose of Humalog® Mix25 during an euglycemic clamp procedure
Study: NCT05373186
Drug: Euglycemic clamp with Humalog® and Lantus®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous administration of Humalog® and Lantus® during an euglycemic clamp procedure
Study: NCT05068726
Drug: 18F Fluoroestradiol Radiopharmaceutical with PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of one dose of 18F FES for PET/CT imaging
Study: NCT05705687
Drug: BEP Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: anticancer therapy
Study: NCT05705687
Drug: Dose-dense regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-BEP-Oxaliplatin followed by Cisplatin - Ifosfamide - Paclitaxel
Study: NCT05891366
Drug: WAL0921
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational product WAL0921
Study: NCT05891366
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo product
Study: NCT05368831
Drug: NST-1024
Normalized name: GLOVE NITRILE SM PFREE NSTERL TX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Drug interactions between NST-1024 and caffeine (and paraxanthine), flurbiprofen, omeprazole, metoprolol, and midazolam
Study: NCT05243940
Drug: remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil infusion under the Minto model (target controlled infusion-TCI aiming at 4ng/ml blood concentration
Study: NCT06425224
Drug: Standard treatment (dapoxetine 30 mg as needed)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive dapoxetine 30 mg, taken 3 to 4 hours before sexual intercourse, for the 12 weeks of the study
Study: NCT04919135
Drug: standard frailty treatment and supplementary medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hightamine (Hankook Korus Pharm, Korea), Total calcium (Nugale Pharmaceutical, Canada), Bioflex (Ausbiomed, Australia)
Study: NCT05061758
Drug: LY3056480
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3056480 is an inhibitor of gamma-secretase
Study: NCT06253702
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: to inhibit cyclooxygenase (COX)
Study: NCT06253702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06208410
Drug: Capecitabine Tablets
Normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine Tablets is administered once daily, orally
Study: NCT06253702
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg each morning for add back phase (male participants)
Study: NCT06253702
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women will receive oral estradiol 2mg/daily
Study: NCT04615949
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
Study: NCT04905563
Drug: Acetaminophen-Hydrocodone
Normalized name: acetaminophen-hydrocodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narcotic
Study: NCT05004363
Drug: Lokelma Oral Product
Normalized name: Lokelma Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium binder
Study: NCT06104449
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets to be taken orally as a recue medication.
Study: NCT05363449
Drug: UHE-103 Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: UHE-103 is an investigational combinational therapy containing keratolytic and antifungal
Study: NCT05058976
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly saline injection
Study: NCT05058976
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 mg IV infusion at Month 12 Visit
Study: NCT05794672
Drug: Elarekibep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive single or multiple inhaled doses A, B or C, or single IV dose D of elarekibep.
Study: NCT05794672
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive single or multiple inhaled doses A, B or C.
Study: NCT05681650
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously at a total dose of 15-30mg/kg on day -3 and day-2
Study: NCT06425861
Drug: THB335 single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose as oral capsule
Study: NCT06425861
Drug: Single dose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose as oral capsule
Study: NCT06425861
Drug: THB335 fasted/fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose fasted and fed as oral capsule
Study: NCT06425861
Drug: Placebo fasted/fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose fasted and fed as oral capsule
Study: NCT04669028
Drug: NE3107
Approvals — FDA: no, EMA: no, PMDA: no
Description: NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Alzheimer's disease.
Study: NCT04669028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules that do not contain NE3107
Study: NCT06425861
Drug: THB335 multiple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending doses oral capsule
Study: NCT06425861
Drug: Multiple dose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses oral capsule
Study: NCT05387083
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy Volunteers will receive a single dose of placebo on Day 1.
Study: NCT05177939
Drug: NPB-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPB-01 will be administered for the treatment of autoimmune encephalitis
Study: NCT06147544
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously once a week
Study: NCT05941793
Drug: MBS-COV
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBS-COV for inhalation
Study: NCT05941793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for inhalation
Study: NCT06511973
Drug: Naproxen (BAYH006689)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BAYH006689 gel will be dispensed directly on the patch
Study: NCT06511973
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel will be dispensed directly on the patch
Study: NCT06511973
Drug: A solution of 0.9% Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Saline will be dispensed directly on the patch
Study: NCT06511973
Drug: A solution of 0.2% SLS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% SLS will be dispensed directly on the patch.
Study: NCT05032261
Drug: Circulatory shock with norepinephrine in ICU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circulatory shock with norepinephrine in ICU
Study: NCT05686239
Drug: RL-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: investigational study drug
Study: NCT05686239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules matching the appearance and size of the active drug
Study: NCT04594798
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV 400 mg/m2 per cycle
Study: NCT04594798
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV 25 mg/m2 per cycle
Study: NCT05612191
Drug: AL3818
Approvals — FDA: no, EMA: no, PMDA: no
Description: It inhibits VEGFR2-mediated downstream signal transduction, thereby inhibiting tumor angiogenesis. It also has high potency against FGFr as well as VEGFr, and as such acts as a mainly dual inhibitor.
Study: NCT05671692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same as active comparator, except placebo dispensed.
Study: NCT04986202
Drug: AZD4831
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4831
Study: NCT05180851
Drug: Recombinant L-IFN adenovirus injection
Normalized name: COVID-19 VACCINE ADENOVIRUS-26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before use, dilute the product with normal saline according to the size of the tumor to an appropriate volume (10-30% of the total volume of the tumor), or adjust appropriately according to the specific tumor situation, inject directly into the tumor or inject under the guidance of B ultrasound /CT, inject the drug solution into the tumor edge and tumor evenly
Study: NCT05104853
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNP-104 Placebo
Study: NCT04922814
Drug: muscle relaxation
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: They will receive muscle relaxation treatment for at least 48 hours. Cisatracurium will be given. Short term infusions up to 24 hours will be given in a dose rate of 2-3 mic/Kg/min followed by intervallic shots of 2-5 mg.
Study: NCT06257966
Drug: Exendin-4 Fc fusion protein injection(1.2mg）
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2mg, subcutaneous injection in the abdomen, biweekly, 54 weeks of treatment.
Study: NCT00396968
Drug: AMD3100
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05302999
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert cellulose
Study: NCT04033029
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic concentration-time data will be collected and analyzed.
Study: NCT06257966
Drug: Exendin-4 Fc fusion protein injection（2.4mg）
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first dose of 1.2 mg was administered subcutaneously in the abdomen, and after two weeks, the dose was adjusted to 2.4 mg, followed by a continuation of treatment for 52 weeks.
Study: NCT00002403
Drug: Zintevir
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05007587
Drug: mFOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAIC was performed every 3 weeks. The mFOLFOX regimen was administered via hepatic artery: oxaliplatin , 85mg/m2 , from hour 0 to 2 on day1 ; leucovorin , 400mg/m2 , from hour 2 to 3 on day 1 ; fluorouracil , 400mg/m2 , bolus at hour 3 ; and 2400mg/m2 over 46 hours on days 1 and 2.3mg/m2 , from hour 4 to 5 on day 1.
Study: NCT05007587
Drug: ROX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAIC was performed every 3 weeks. The ROX regimen was administered via hepatic artery: oxaliplatin , 100mg/m2 , from hour 0 to 4 on day1 ;raltitrexed , 3mg/m2 , from hour 4 to 5 on day 1.
Study: NCT05538689
Drug: Myfembree Oral Product
Normalized name: Myfembree Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study drug Myfembree will be taken orally with water, once daily, at approximately the same time, with or without food. Each tablet of Myfembree contains Relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5 mg.
Study: NCT04716426
Drug: Tetracycline hydrochloride 3%
Normalized name: Tetracycline Hydrochloride 3% Topical application Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprietary formulation composed of FDA approved inactive ingredients and the active pharmaceutical ingredient tetracycline hydrochloride.
Study: NCT04716426
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation composed of FDA approved inactive ingredients.
Study: NCT04163536
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: in the control group, placebo will be administered intravenously for 5 days. Placebo will be identical (color and aspect) to experimental substance, will be provide as a 50 mL of NaCl 0.9% solution and administered intravenously over 15 minutes, once a day.
Study: NCT00588926
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the mapping electrode is in situ, recording of baseline electrical activity is done for two-three minutes and an infusion of Remifentanil, 0.1 microgram per kilogram per minute is started. This procedure continues for a few minutes until the patient is sedated and then the infusion is stopped and the patient allowed to recover. The recordings continue during the whole procedure.
Study: NCT04844970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anamorelin placebo
Study: NCT05119998
Drug: IBI325
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI325 monotherapy does-escalation Patients will receive IBI325 until progressive disease, intolerability, or other reasons leading to treatment discontinuation
Study: NCT05634382
Drug: Intravenous thrombolysis agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis with recombinant tissue-type plasminogen activator (rt-PA，alteplase) or TNK-tPA (Tenecteplase，Metalyse)
Study: NCT05018013
Drug: Placebo to Ammoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Ammoxetine
Study: NCT05706870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06617312
Drug: Cytisinicline
Normalized name: cytisinicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targets α4β2 nicotinic acetylcholine receptors
Study: NCT06617312
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched to active drug, cytisinicline